The Serum Institute of India (SII) is currently working on an Omicron-specific vaccine, which is expected to be launched by the end of the year, said CEO Adar Poonawalla said on Monday.
Serum Institute is working with Novavax to bring the Omicron-specific vaccine, as India continues to record a surge in the number of Covid-19 cases. The new vaccine will be "specific to the BA5 sub-variant of Omicron, for which the UK has approved an updated Moderna vaccine. The bivalent vaccine targets the Omicron variant as well as the original form," NDTV reported.
Also Read: What is Chikungunya?
Also Read: What is Chikungunya?